Senseonics Holdings, Inc. Common Stock

Beta Bionics announced a partnership with Senseonics to expand compatibility between its automated insulin delivery platform and Senseonics' continuous glucose monitoring technology. The integrated iLet and Eversense 365 system is expected to launch commercially in the fourth quarter of 2026, after which the iLet is expected to support Dexcom G6, Dexcom G7, Abbott's FreeStyle Libre 3 Plus and Senseonics' Eversense 365, which Beta Bionics expects will make the iLet compatible with more CGM manufacturers than any other AID system. Beta Bionics also intends to integrate its next-generation mint AID system with Eversense 365 in the future. Following the Sept. 22 announcement, shares of BBNX lost more than 8% in the next trading session and have lost 32.6% year to date, compared with the industry's 4.9% decline, leaving the company with a market capitalization of $967.7 million. Separately, BBNX recently secured FDA clearance for its Mint patch pump and unveiled its next-generation 3D Intelligence insulin dosing algorithm, which is currently under FDA review.